ASH 2022 | Clinical screening for Ph-like ALL and trials available to pediatric patients
In this video, Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, highlights an educational session that took place at this year’s ASH Meeting which focused on clinical diagnostics for pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), and further discusses clinical trial options for these patients, including the AALL1521 and AALL1631 trials (NCT02723994; NCT03007147). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Aleta Biotherapeutics: Consultancy; Beam Therapeutics: Research Funding; bluebird bio: Consultancy; Syndax Pharmaceuticals: Consultancy; Kura Oncology: Consultancy, Research Funding; GSK: Consultancy; Incyte Corporation: Research Funding.
